Christie Louis
Women's Health · Houston, TXNPI 1720312564
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,738 of the $3,426 with a category attached, or 79.9%. 23 manufacturers reported payments, led by Medtronic at 27.1% of the total. Reporting peaked in 2023 at $1,677 and has fallen 65.1% since, to $585 in 2025. Among women's health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$930
- Astellas Pharma US Inc$576
- Bayer$389
- Sumitomo Pharma America, Inc.$280
- Boston Scientific$160
- Integra Lifesciences Corporation$151
- plus $940 from 17 others
Across 1 payment — averaging $140.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$140
What the payments were for
- Travel & lodging$58617%
- Food & beverage$2,73880%
- Education$1023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 11 | $930 |
| Astellas Pharma US Inc | 21 | $576 |
| Bayer | 18 | $389 |
| Sumitomo Pharma America, Inc. | 18 | $280 |
| Boston Scientific | 2 | $160 |
| Integra Lifesciences Corporation | 1 | $151 |
| Mayne Pharma Commercial LLC | 8 | $150 |
| Acella Pharmaceuticals, LLC | 1 | $130 |
| Pacira Pharmaceuticals Incorporated | 4 | $95 |
| Urovant Sciences Inc | 1 | $90 |
| Organon | 5 | $87 |
| Scynexis, Inc. | 4 | $85 |
| Myovant Sciences Inc. | 5 | $76 |
| Hologic Sales And Service, LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Exeltis, USA Inc. | 2 | $38 |
| Mycovia Pharmaceuticals, Inc. | 1 | $26 |
| Axonics, Inc. | 1 | $15 |
| Biotissue Holdings Inc. | 1 | $15 |
| Evofem Biosciences, Inc. | 2 | $14 |
| Amgen | 1 | $13 |
| Millicent US Inc | 1 | $13 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$452
- INTERSTIM$436
- INTEGRA DERMAL REGENERATION TEMPLATE$151
- PRIMATRIX$151
- Solyx SIS System$141
- NP Thyroid 60$130
- Veozah$125
How this compares
$3,426 in reported general payments places this provider in the 95th percentile of 609 women's health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 160 | $108,107 |
| MyrbetriqMirabegron | 95 | $58,505 |
| Estradiol | 198 | $12,939 |
| Mirabegron ErMirabegron | 23 | $10,320 |
| PremarinEstrogens, Conjugated | 18 | $7,620 |
| EstringEstradiol | 13 | $6,650 |
| Trospium Chloride ErTrospium Chloride | 13 | $4,546 |
| Methenamine Hippurate | 37 | $3,749 |
| Solifenacin Succinate | 39 | $2,909 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 91 | $1,431 |
| Clobetasol Propionate | 29 | $1,315 |
| Trospium Chloride | 14 | $867 |
| NitrofurantoinNitrofurantoin Macrocrystal | 26 | $534 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $349 |
| Amitriptyline Hcl | 15 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $280 | $108,107160 claims |
| Astellas Pharma US IncMyrbetriq | $576 | $58,50595 claims |
| PfizerPremarin, Estring | $13 | $14,27031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 609 women's health providers in Texas.
Other women's health in Houston
- Joann St PierreHouston$15K
- Lori WinkHouston$9K
- Andrea DunnHouston$6K
- Kim GustafsonHouston$4K
- Erica SmithHouston$4K
- Mary UmbleHouston$3K
- Kim OkewunmiHouston$3K
- Kathryn AckermanHouston$2K
- Evelyn TingGrapevine$89K
- Christina TrumanWaco$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.